Answers are grounded in this paper and cite their sources.
Activating mutations of FLT3 (FMS-Like Tyrosine kinase-3) are the most common molecular abnormality in acute myeloid leukemia (AML). Their presence is associated with a worse prognosis, and the recognition of this has led to the development of several new small molecule FLT3 tyrosine kinase inhibitors. In this review, we summarize these developments and compare and contrast these novel agents both with regards to the assays used to characterize them as well as to their clinical potential.
No takes yet. Share an insight, caveat, or question.
Levis et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: